-
![SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS](/abs-image/US/2018/05/17/US20180133207A1/abs.jpg.150x150.jpg)
公开(公告)号：US20180133207A1
公开(公告)日：2018-05-17
申请号：US15860894
申请日：2018-01-03
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls
IPC: A61K31/4545 , A61K45/06 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/506 , A61K31/501 , A61K31/497 , A61K31/5377
CPC classification number: A61K31/4545 , A61K31/4162 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/00 , A61P1/12 , A61P35/00 , A61P35/02 , C07D471/04
Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors](/abs-image/US/2018/12/04/US10144734B2/abs.jpg.150x150.jpg)
公开(公告)号：US10144734B2
公开(公告)日：2018-12-04
申请号：US15858929
申请日：2017-12-29
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls
IPC: C07D471/04 , A61K31/4162 , A61P1/00 , A61P35/00
Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors](/abs-image/US/2018/11/27/US10137124B2/abs.jpg.150x150.jpg)
公开(公告)号：US10137124B2
公开(公告)日：2018-11-27
申请号：US15860852
申请日：2018-01-03
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: A61K31/437 , A61K31/496 , C07D471/04 , A61P1/12 , A61P35/04 , C07D519/00 , A61P35/02 , A61P35/00 , A61K31/444 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K45/06 , A61K31/551
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS](/abs-image/US/2018/05/17/US20180133200A1/abs.jpg.150x150.jpg)
公开(公告)号：US20180133200A1
公开(公告)日：2018-05-17
申请号：US15860852
申请日：2018-01-03
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: A61K31/444 , A61K31/496 , A61P35/00 , A61P35/02 , A61K45/06 , A61K31/5377 , A61K31/4985 , A61K31/506 , A61K31/551
CPC classification number: C07D471/04 , A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K31/551 , A61K45/06 , A61P1/12 , A61P35/00 , A61P35/02 , A61P35/04 , C07D519/00
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors](/abs-image/US/2023/03/14/US11603374B2/abs.jpg.150x150.jpg)
公开(公告)号：US11603374B2
公开(公告)日：2023-03-14
申请号：US16962345
申请日：2019-01-18
Applicant: Array BioPharma Inc.
Inventor： James F. Blake , Donghua Dai , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Andrew T. Metcalf , David A. Moreno , Brett Prigaro , Ginelle A. Ramann , Li Ren
IPC: C07D487/04
Abstract: Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
Patent Agency Ranking
![Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors](/abs-image/US/2021/03/23/US10953005B1/abs.jpg.150x150.jpg)
公开(公告)号：US10953005B1
公开(公告)日：2021-03-23
申请号：US16739846
申请日：2020-01-10
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: C07D401/02 , C07D401/10 , A61K31/437 , A61K31/4353 , A61K31/496 , C07D471/04 , A61P1/12 , A61P35/04 , C07D519/00 , A61P35/02 , A61K31/551 , A61K31/444 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P35/00
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors](/abs-image/US/2019/10/15/US10441581B2/abs.jpg.150x150.jpg)
公开(公告)号：US10441581B2
公开(公告)日：2019-10-15
申请号：US15860894
申请日：2018-01-03
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls
IPC: C07D471/04 , A61K31/4162 , A61K31/4545 , A61P1/00 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/12
Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS](/abs-image/US/2018/05/17/US20180133213A1/abs.jpg.150x150.jpg)
公开(公告)号：US20180133213A1
公开(公告)日：2018-05-17
申请号：US15860808
申请日：2018-01-03
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: A61K31/496 , A61P35/00 , A61K31/5377 , A61K31/4985 , A61K31/506 , A61K31/4995 , A61P35/02 , A61K45/06 , A61K31/444
CPC classification number: A61K31/496 , A61K31/444 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K31/551 , A61K45/06 , A61P1/12 , A61P35/00 , A61P35/02 , A61P35/04 , C07D471/04 , C07D519/00
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors](/abs-image/US/2019/01/08/US10172851B2/abs.jpg.150x150.jpg)
公开(公告)号：US10172851B2
公开(公告)日：2019-01-08
申请号：US15860808
申请日：2018-01-03
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: C07D401/02 , C07D401/10 , A61K31/437 , A61K31/4353 , A61K31/496 , C07D471/04 , A61P1/12 , A61P35/04 , C07D519/00 , A61P35/02 , A61P35/00 , A61K31/444 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K45/06 , A61K31/551
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors](/abs-image/US/2019/01/08/US10172845B2/abs.jpg.150x150.jpg)
公开(公告)号：US10172845B2
公开(公告)日：2019-01-08
申请号：US15861244
申请日：2018-01-03
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls
IPC: A61K31/437 , A61K31/4353 , A61K31/4545 , A61K31/4162 , C07D471/04 , A61P1/00 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/12
Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.075 seconds)
